Drugs / IDP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07602842 | Jun 2026 → Jun 2028 expected | anal squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma +3 | InduPro, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07602842 ↗ |
| Route | Intravenous | “Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.” NCT07602842 ↗ |